Market Movers (8-K)
See all →Filana Therapeutics announced the appointment of biopharma executive Jill M. Quigley to its Board of Directors, bringing extensive leadership and financing experience.
Filana Therapeutics announced Q3 2026 financial results, highlighting the FDA's lift of a clinical hold for simufilam in TSC-related epilepsy, with patient screening expected by Q1 2027.
Filana Therapeutics, Inc. announced that the Fifth Circuit Court of Appeals vacated a lower court's order granting class certification in a securities class action lawsuit against the company.
Filana Therapeutics announced the FDA has lifted its clinical hold on simufilam, allowing the company to proceed with a Phase 2a study for TSC-related epilepsy, with patient screening expected by Q1 2027.
Filana Therapeutics received a notice from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement for its common stock.
Worse than expected
Filana Therapeutics reported Q2 2026 financial results, showing reduced operating expenses and net loss, while continuing to address an FDA clinical hold on its TSC-related epilepsy therapy.
Delay expected
Quarterly Earnings (10-Q)
See all →Filana Therapeutics reports significant progress in resolving legal matters and a clinical hold on its simufilam IND, while R&D expenses decrease due to program shifts.
Delay expected
Capital raise
Filana Therapeutics reports a net loss of $10.3 million for Q1 2026 as it pivots focus to TSC-related epilepsy research.
Delay expected
Capital raise
Cassava Sciences reported a net loss of $10.8 million for Q3 2025, discontinuing its Alzheimer's program to focus on TSC-related epilepsy with a new Yale license.
Capital raise
Worse than expected
Cassava Sciences reports significant losses and discontinues its Alzheimer's drug program, pivoting to a new epilepsy indication while facing substantial legal costs.
Capital raise
Worse than expected
Cassava Sciences is pivoting its focus to Tuberous Sclerosis Complex (TSC) after Phase 3 trials for its Alzheimer's drug, simufilam, failed to meet endpoints, leading to the discontinuation of its Alzheimer's program.
Worse than expected
10-Q: Cassava Sciences Reports Third Quarter 2024 Financial Results and Provides Clinical Program Updates
Cassava Sciences' Phase 3 Alzheimer's drug Simufilam shows promise in trials, with top-line results for the 52-week study expected by the end of 2024, despite ongoing legal challenges and leadership changes.
Worse than expected
Capital raise
Annual Reports (10-K)
Filana Therapeutics, formerly Cassava Sciences, has discontinued its Alzheimer's program, pivoted to TSC-related epilepsy, and faces a clinical hold on its lead candidate, simufilam, while settling significant legal claims.
Delay expected
Worse than expected
Capital raise
Cassava Sciences reports discontinuation of Alzheimer's clinical trials, a settlement with the SEC, and a strategic shift towards Tuberous Sclerosis Complex (TSC)-related epilepsy in its 2024 10-K filing.
Worse than expected
Cassava Sciences outlines its common stock and warrant details, including authorized shares, voting rights, and warrant exercise conditions, in its annual 10-K filing.
Capital raise
Insider Trading (Form 4)
See all →Robert Eugene Anderson Jr, a Director of Cassava Sciences Inc, purchased 19,000 shares of common stock on November 18, 2026 for $0.52 per share.
Form 4: Cassava Sciences CEO Buys Shares
Richard Barry, President & CEO and a Director of Cassava Sciences Inc, purchased 44,851 shares of common stock on November 18, 2026 for $0.52 per share.
Form 4: Cassava Sciences CEO Buys Shares
Richard Barry, President & CEO and a Director of Cassava Sciences Inc, purchased 132,926 shares of common stock on November 17, 2026 for $0.48 per share.
Form 4: Cassava Sciences CEO Buys Shares
Richard Barry, President & CEO and a Director of Cassava Sciences Inc, purchased 440,206 shares of common stock on November 16, 2026 for $0.47 per share.
Form 4: Cassava Sciences CFO Buys Shares
Eric Schoen, Chief Financial Officer of Cassava Sciences Inc, purchased 20,000 shares of common stock on November 16, 2026 for $0.42 per share.
Form 4: Cassava Sciences COO Buys Shares
Robert Christopher Cook, Chief Operating& Legal Officer of Cassava Sciences Inc, purchased 121,575 shares of common stock on November 16, 2026 for $0.46 per share.
Proxy Statements (Def-14A)
Cassava Sciences seeks shareholder approval for increased director compensation and a reduction in board classification from three to two classes at its upcoming annual meeting.
Cassava Sciences will hold its 2024 Annual Meeting of Stockholders virtually on May 9, 2024, to vote on director elections, auditor ratification, and executive compensation.
Schedule 13G - Passive Investments
The Vanguard Group has updated its beneficial ownership in Cassava Sciences Inc., reporting a 4.49% stake as of June 30, 2025, falling below the 5% Schedule 13G reporting threshold.
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 3.2% passive beneficial ownership stake in Cassava Sciences Inc. as of June 30, 2025.